DK1924574T3 - Fremgangsmåde til syntese af 5-(methyl-1H-imidazol-1-yl)-3-(trifluormethyl)-benzenamin - Google Patents

Fremgangsmåde til syntese af 5-(methyl-1H-imidazol-1-yl)-3-(trifluormethyl)-benzenamin

Info

Publication number
DK1924574T3
DK1924574T3 DK06772448.4T DK06772448T DK1924574T3 DK 1924574 T3 DK1924574 T3 DK 1924574T3 DK 06772448 T DK06772448 T DK 06772448T DK 1924574 T3 DK1924574 T3 DK 1924574T3
Authority
DK
Denmark
Prior art keywords
benzenamine
imidazol
trifluoromethyl
synthesis
methyl
Prior art date
Application number
DK06772448.4T
Other languages
English (en)
Inventor
Joseph Mckenna
Wen-Chung Shieh
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK1924574T3 publication Critical patent/DK1924574T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Steroid Compounds (AREA)
DK06772448.4T 2005-06-09 2006-06-07 Fremgangsmåde til syntese af 5-(methyl-1H-imidazol-1-yl)-3-(trifluormethyl)-benzenamin DK1924574T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68897705P 2005-06-09 2005-06-09
US70559005P 2005-08-04 2005-08-04
PCT/US2006/022155 WO2006135641A2 (en) 2005-06-09 2006-06-07 PROCESS FOR THE SYNTHESIS OF 5- (METHYL-lH-IMIDAZOL-l-YL) -3- (TRI FLUOROME TH YL) -BENZENEAMINE

Publications (1)

Publication Number Publication Date
DK1924574T3 true DK1924574T3 (da) 2011-02-14

Family

ID=37091153

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06772448.4T DK1924574T3 (da) 2005-06-09 2006-06-07 Fremgangsmåde til syntese af 5-(methyl-1H-imidazol-1-yl)-3-(trifluormethyl)-benzenamin

Country Status (32)

Country Link
US (2) US8124763B2 (da)
EP (1) EP1924574B1 (da)
JP (1) JP5118024B2 (da)
KR (3) KR101514593B1 (da)
AR (1) AR053890A1 (da)
AT (1) ATE487709T1 (da)
AU (1) AU2006258051B2 (da)
BR (1) BRPI0611663A2 (da)
CA (1) CA2610105C (da)
CY (1) CY1111428T1 (da)
DE (1) DE602006018156D1 (da)
DK (1) DK1924574T3 (da)
EC (1) ECSP077982A (da)
EG (1) EG25039A (da)
GT (1) GT200600217A (da)
HK (1) HK1117524A1 (da)
IL (1) IL187421A (da)
JO (1) JO2636B1 (da)
MA (1) MA29599B1 (da)
MX (1) MX2007015423A (da)
MY (1) MY147436A (da)
NO (1) NO340743B1 (da)
NZ (1) NZ563740A (da)
PE (1) PE20070015A1 (da)
PL (1) PL1924574T3 (da)
PT (1) PT1924574E (da)
RU (1) RU2444520C2 (da)
SA (1) SA06270147B1 (da)
SI (1) SI1924574T1 (da)
TN (1) TNSN07463A1 (da)
TW (1) TWI430999B (da)
WO (1) WO2006135641A2 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200600316A (es) * 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
CA2689989A1 (en) 2007-06-04 2008-12-11 Avila Therapeutics, Inc. Heterocyclic compounds and uses thereof
US20100016590A1 (en) * 2008-07-17 2010-01-21 Teva Pharmaceutical Industries Ltd. Nilotinib intermediates and preparation thereof
CN102203084B (zh) 2008-11-05 2014-10-29 特瓦制药工业有限公司 盐酸尼洛替尼晶型
WO2010060074A1 (en) * 2008-11-24 2010-05-27 Teva Pharmaceutical Industries Ltd. Preparation of nilotinib and intermediates thereof
US20110053968A1 (en) * 2009-06-09 2011-03-03 Auspex Pharmaceuticals, Inc. Aminopyrimidine inhibitors of tyrosine kinase
JO3634B1 (ar) 2009-11-17 2020-08-27 Novartis Ag طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
EP2691539B1 (en) 2011-03-31 2018-04-25 The Procter and Gamble Company Methods for identifying and evaluating skin-active agents effective for treating dandruff
AR086913A1 (es) * 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
WO2013120852A1 (en) 2012-02-13 2013-08-22 Grindeks, A Joint Stock Company Intermediates for a novel process of preparing imatinib and related tyrosine kinase inhibitors
WO2013184908A2 (en) 2012-06-06 2013-12-12 The Procter & Gamble Company Systems and methods for identifying cosmetic agents for hair/scalp care compositions
WO2015092624A1 (en) 2013-12-16 2015-06-25 Ranbaxy Laboratories Limited Nilotinib mono-oxalate and its crystalline form
CN103694176B (zh) 2014-01-07 2015-02-18 苏州立新制药有限公司 尼洛替尼中间体的制备方法
EP3095782A1 (en) 2015-05-18 2016-11-23 Esteve Química, S.A. New method for preparing 3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)benzenamine
CN111683976B (zh) 2018-02-05 2022-11-18 生物辐射实验室股份有限公司 具有阴离子交换-疏水混合模式配体的色谱树脂
CN113292537B (zh) 2018-06-15 2024-04-05 汉达癌症医药责任有限公司 激酶抑制剂的盐类及其组合物
JP2020007240A (ja) * 2018-07-04 2020-01-16 住友化学株式会社 ベンズアミド化合物の製造方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5136082A (en) * 1990-08-03 1992-08-04 Himont Incorporated Process for preparing organic esters and amides and catalyst system therefor
WO1994014415A1 (en) 1992-12-24 1994-07-07 Hemagen/Pfc Fluorocarbon emulsions
TW406020B (en) 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5597829A (en) 1994-05-09 1997-01-28 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of camptothecin and methods for uses thereof
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US6323366B1 (en) 1997-07-29 2001-11-27 Massachusetts Institute Of Technology Arylamine synthesis
AR013261A1 (es) 1997-08-01 2000-12-13 Smithkline Beecham Corp Formulaciones farmaceuticas para analogos de camptotecina en capsula de gelatina
US20030059465A1 (en) 1998-05-11 2003-03-27 Unger Evan C. Stabilized nanoparticle formulations of camptotheca derivatives
US6395916B1 (en) * 1998-07-10 2002-05-28 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
ATE216998T1 (de) 1999-03-09 2002-05-15 Sigma Tau Ind Farmaceuti Camptothecin-derivate mit antitumor-wirkung
IT1306129B1 (it) 1999-04-13 2001-05-30 Sigma Tau Ind Farmaceuti Esteri della l-carnitina o di alcanoil l-carnitine utilizzabili comelipidi cationici per l'immissione intracellulare di composti
DE19926056B4 (de) 1999-06-08 2004-03-25 Gkss-Forschungszentrum Geesthacht Gmbh Einrichtung zur Analyse atomarer und/oder molekularer Elemente mittels wellenlängendispersiver, röntgenspektrometrischer Einrichtungen
GB9918885D0 (en) 1999-08-10 1999-10-13 Pharmacia & Upjohn Spa Pharmaceutical formulations in hydroxypropymethycellulose capsules
GB9925127D0 (en) 1999-10-22 1999-12-22 Pharmacia & Upjohn Spa Oral formulations for anti-tumor compounds
US20040009229A1 (en) 2000-01-05 2004-01-15 Unger Evan Charles Stabilized nanoparticle formulations of camptotheca derivatives
US20020150615A1 (en) 2001-02-12 2002-10-17 Howard Sands Injectable pharmaceutical composition comprising microdroplets of a camptothecin
US6629598B2 (en) 2001-08-10 2003-10-07 Vinod K. Narula Flexible ribbed splint system
US6653319B1 (en) 2001-08-10 2003-11-25 University Of Kentucky Research Foundation Pharmaceutical formulation for poorly water soluble camptothecin analogues
ES2625340T3 (es) 2001-10-15 2017-07-19 Crititech, Inc. Composiciones y métodos para la administración de fármacos escasamente solubles en agua y métodos de tratamiento
WO2003057128A2 (en) 2001-12-11 2003-07-17 Dor Biopharma, Inc. Lipid particles and suspensions and uses thereof
JP2003267891A (ja) 2002-03-13 2003-09-25 Mitsubishi-Kagaku Foods Corp W/o/w型エマルション製剤
FR2840303B1 (fr) * 2002-05-31 2005-07-15 Rhodia Chimie Sa Procede d'arylation ou de vinylation ou d'alcylynation d'un compose nucleophile
CZ294371B6 (cs) 2002-06-10 2004-12-15 Pliva - Lachema, A. S. Stabilizovaná farmaceutická kompozice na bázi polyoxyethylovaného ricinového oleje a způsob její přípravy
EP1393719A1 (en) 2002-08-23 2004-03-03 Munich Biotech AG Camptothecin-carboxylate formulations
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
JP4426749B2 (ja) 2002-07-11 2010-03-03 株式会社産学連携機構九州 O/w型エマルション製剤
US20040171560A1 (en) 2002-12-23 2004-09-02 Dabur Research Foundation Stabilized pharmaceutical composition
JP2006199590A (ja) 2003-09-04 2006-08-03 Nano Career Kk 水溶性の塩基性薬物内包ナノ粒子含有組成物
DE602004027936D1 (de) 2003-10-29 2010-08-12 Sonus Pharmaceutical Inc Tocopherolmodifizierte therapeutische arzneimittelverbindung
DK1694242T3 (da) 2003-12-17 2014-06-30 Bionumerik Pharmaceuticals Inc Fremgangsmåde til fremstilling af farmaceutiske 7-(2-trimethylsilylethyl)camptothecinpræparater
GT200500310A (es) 2004-11-19 2006-06-19 Compuestos organicos

Also Published As

Publication number Publication date
ATE487709T1 (de) 2010-11-15
NO20080157L (no) 2008-01-09
KR101216249B1 (ko) 2012-12-28
MX2007015423A (es) 2008-02-21
DE602006018156D1 (de) 2010-12-23
GT200600217A (es) 2007-03-28
AU2006258051A1 (en) 2006-12-21
CA2610105A1 (en) 2006-12-21
PT1924574E (pt) 2011-02-08
PL1924574T3 (pl) 2011-04-29
AR053890A1 (es) 2007-05-23
CA2610105C (en) 2014-03-25
RU2007148231A (ru) 2009-07-20
MY147436A (en) 2012-12-14
TWI430999B (zh) 2014-03-21
WO2006135641A3 (en) 2007-03-29
HK1117524A1 (en) 2009-01-16
PE20070015A1 (es) 2007-02-06
WO2006135641A2 (en) 2006-12-21
KR101514593B1 (ko) 2015-04-22
TW200726756A (en) 2007-07-16
BRPI0611663A2 (pt) 2010-09-28
EP1924574B1 (en) 2010-11-10
SA06270147B1 (ar) 2009-12-22
US8124763B2 (en) 2012-02-28
SI1924574T1 (sl) 2011-02-28
US20120116081A1 (en) 2012-05-10
JP2008545786A (ja) 2008-12-18
AU2006258051B2 (en) 2010-09-09
ECSP077982A (es) 2008-01-23
KR20120066067A (ko) 2012-06-21
JO2636B1 (en) 2012-06-17
KR20130118394A (ko) 2013-10-29
IL187421A (en) 2011-11-30
CY1111428T1 (el) 2015-08-05
NO340743B1 (no) 2017-06-12
EP1924574A2 (en) 2008-05-28
TNSN07463A1 (en) 2009-03-17
EG25039A (en) 2011-07-06
MA29599B1 (fr) 2008-07-01
IL187421A0 (en) 2008-02-09
KR20080022093A (ko) 2008-03-10
RU2444520C2 (ru) 2012-03-10
US8946416B2 (en) 2015-02-03
NZ563740A (en) 2011-03-31
JP5118024B2 (ja) 2013-01-16
US20080188656A1 (en) 2008-08-07

Similar Documents

Publication Publication Date Title
DK1924574T3 (da) Fremgangsmåde til syntese af 5-(methyl-1H-imidazol-1-yl)-3-(trifluormethyl)-benzenamin
CY2017044I2 (el) Αντισωματα εναντι cd38 για τη θεραπεια του πολλαπλου μυελωματος
DK2292607T3 (da) Fremgangsmåde til syntese af organiske forbindelser
DK1893586T3 (da) Fremgangsmåde til fremstilling af 1-alkyl-3-phenyluraciler
DK3403657T3 (da) Anvendelse af oligouronater til behandling af slimhyperviskositet
DK1877192T5 (da) Fremgangsmåde til fremstilling af fibermateriale
CY2014029I1 (el) Ισοξαζολινες για τον ελεγχο ασπονδυλων παρασιτων
DK2781593T3 (da) Fremgangsmåde til behandling af methanemissioner
DK1828164T3 (da) Fremgangsmåde til fremstilling af N-phenylpyrazol-1-carboxamider
DK1778668T3 (da) Fremgangsmåde til fremstilling af dihydropteridion
DK2423325T3 (da) Fremgangsmåde til fremstilling af biblioteker af template-polynukleotider
DK2046767T3 (da) Fremgangsmåde til fremstilling af diaminophenothiaziniumforbindelser
DK1948176T3 (da) Diarylurinstoffer til behandling af pulmonær hypertension
DK2824183T3 (da) Fremgangsmåde til fremstilling af bispecifikke antistoffer
DK2086944T3 (da) Fremgangsmåde til fremstilling af difluormethylpyrazolylcarboxylater
DK3336073T3 (da) Fremgangsmåde til fremstilling af fluorerede organiske forbindelser
DK3056568T3 (da) Fremgangsmåder til kontrollering af antistoffers blodfarmakokinetik
DK3023500T3 (da) Insektceller til fremstilling af AAV-vektorer
PL1896425T3 (pl) Sposób wytwarzania 5-(metylo-1H-1-ilo)-3-trifluorometylo)-benzenoaminy
DK1937650T3 (da) Heterocykliske forbindelser
DK1881830T3 (da) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinolin-derivater til behandling af infertilitet
DK1831223T3 (da) Fremgangsmåde til fremstilling af L-biopterin
DK1814555T3 (da) S-mirtazapin til behandling af hedeture
FI20055666A0 (fi) Prosessi hiilivetykomponentin valmistamiseksi
DK1906972T3 (da) LPA2-receptoragonist til behandling af diarré